Odyssey Health, Inc. (ODYY)
| Previous Close | 0.0300 |
| Open | 0.0290 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0290 - 0.0290 |
| 52 Week Range | 0.0210 - 0.2350 |
| Volume | |
| Avg. Volume | 96,673 |
| Market Cap | 2.794M |
| Beta (5Y Monthly) | -0.50 |
| PE Ratio (TTM) | 0.29 |
| EPS (TTM) | 0.1000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Odyssey Health, Inc. Strengthens Balance Sheet with $8.7 Million in Net Equity
LAS VEGAS, NV / ACCESSWIRE / March 27, 2024 / Odyssey Health, Inc. (OTCQB:ODYY), formerly Odyssey Group International, Inc., (the "Company") a company focused on developing unique, life-enhancing medical products, recently filed its quarterly report ...
- ACCESSWIRE
Odyssey Health Closes Asset Sale of its Neurological Drug Technology Pipeline Including Concussion Drug Candidate with Oragenics, Inc.
LAS VEGAS, NV / ACCESSWIRE / January 2, 2024 / Odyssey Health, Inc. (OTCQB:ODYY) ("Odyssey" or the "Company") today announces the closing of the definitive Asset Purchase Agreement, that was entered into on October 4, 2023, with Oragenics, Inc., (OGEN:NYSE ...
- ACCESSWIRE
Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.
LAS VEGAS, NV / ACCESSWIRE / December 12, 2023 / Odyssey Health, Inc. (OTCOB:ODYY), a company focused on developing unique, life-enhancing medical products including a drug treatment intended to treat concussion, announces that it has received stockholder ...
